CN110267655A - 氨基酸组合物及肌肉疾病与病症的治疗方法 - Google Patents

氨基酸组合物及肌肉疾病与病症的治疗方法 Download PDF

Info

Publication number
CN110267655A
CN110267655A CN201780078594.XA CN201780078594A CN110267655A CN 110267655 A CN110267655 A CN 110267655A CN 201780078594 A CN201780078594 A CN 201780078594A CN 110267655 A CN110267655 A CN 110267655A
Authority
CN
China
Prior art keywords
amino acid
entity
composition
acid entity
kinds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078594.XA
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈米尔
瑞弗·亚非恩
威廉·康柏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amine Fine Health Co
Original Assignee
Amine Fine Health Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amine Fine Health Co filed Critical Amine Fine Health Co
Publication of CN110267655A publication Critical patent/CN110267655A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201780078594.XA 2016-12-19 2017-12-19 氨基酸组合物及肌肉疾病与病症的治疗方法 Pending CN110267655A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US62/436,073 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US62/443,205 2017-01-06
US201762491776P 2017-04-28 2017-04-28
US62/491,776 2017-04-28
US201762545358P 2017-08-14 2017-08-14
US62/545,358 2017-08-14
US201762576321P 2017-10-24 2017-10-24
US62/576,321 2017-10-24
PCT/US2017/067368 WO2018118957A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of muscle diseases and disorders

Publications (1)

Publication Number Publication Date
CN110267655A true CN110267655A (zh) 2019-09-20

Family

ID=61025047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078594.XA Pending CN110267655A (zh) 2016-12-19 2017-12-19 氨基酸组合物及肌肉疾病与病症的治疗方法

Country Status (21)

Country Link
US (3) US20180207119A1 (enExample)
EP (1) EP3554493A1 (enExample)
JP (1) JP2020502183A (enExample)
KR (1) KR20190099243A (enExample)
CN (1) CN110267655A (enExample)
AU (1) AU2017379825A1 (enExample)
BR (1) BR112019012476A2 (enExample)
CA (1) CA3046558A1 (enExample)
CL (1) CL2019001685A1 (enExample)
CO (1) CO2019006292A2 (enExample)
CU (1) CU20190057A7 (enExample)
EC (1) ECSP19043725A (enExample)
IL (1) IL267210A (enExample)
JO (1) JOP20190147A1 (enExample)
MA (1) MA50763A (enExample)
MX (1) MX2019007352A (enExample)
PE (1) PE20191206A1 (enExample)
PH (1) PH12019501339A1 (enExample)
TW (1) TWI780096B (enExample)
WO (1) WO2018118957A1 (enExample)
ZA (1) ZA201903581B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
CN113288890A (zh) * 2021-06-21 2021-08-24 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3615018A1 (en) 2017-04-28 2020-03-04 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
MX2020001766A (es) * 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de lesion neuronal.
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2019246310A1 (en) * 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the reduction or treatment of inflammation
US11679089B2 (en) 2018-06-20 2023-06-20 Axcella Health Inc. Methods of manufacturing amino acid compositions
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
CN112752575A (zh) * 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
WO2020245299A1 (en) 2019-06-07 2020-12-10 Société des Produits Nestlé S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
KR102456270B1 (ko) * 2019-09-24 2022-10-19 마이오텍사이언스 주식회사 비천연 아미노산 유도체를 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
KR102338447B1 (ko) * 2019-09-24 2021-12-14 마이오텍사이언스 주식회사 비천연 아미노산을 함유하는 근감소증의 예방 또는 치료용 약학적 조성물
US20220331290A1 (en) * 2019-09-24 2022-10-20 Myo-Tec-Sci Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid
US20230089723A1 (en) * 2020-03-06 2023-03-23 Axcella Health Inc. Amino acid compositions and methods for muscle and myotube modulation
KR102802853B1 (ko) * 2021-02-26 2025-05-07 이엑스헬스케어 주식회사 피부 유래 엑소좀을 통해 근손실 억제 또는 근생성 촉진 효과를 나타내는 조성물
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
CN1684676A (zh) * 2002-09-20 2005-10-19 诺瓦提斯公司 富含亮氨酸的营养组合物
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
CN101049500A (zh) * 2007-02-15 2007-10-10 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
WO2013028547A1 (en) * 2011-08-19 2013-02-28 Musclepharm Corporation Compositions and methods for use in promoting lean body mass

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105112A2 (en) * 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
WO2015061607A1 (en) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Mtorc1 modulation by amino acids and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
CN1684676A (zh) * 2002-09-20 2005-10-19 诺瓦提斯公司 富含亮氨酸的营养组合物
US20060002913A1 (en) * 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
CN101049500A (zh) * 2007-02-15 2007-10-10 北京苏里曼医药科技有限公司 一种氨基酸组合物
WO2013028547A1 (en) * 2011-08-19 2013-02-28 Musclepharm Corporation Compositions and methods for use in promoting lean body mass

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID S. WISHART: "HMDB: the Human Metabolome Database", 《NUCLEIC ACIDS RESEARCH》 *
顾新刚 等: "丰诺安治疗危重病肝功能损害疗效观察", 《岭南急诊医学杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110801007A (zh) * 2019-12-17 2020-02-18 苟春虎 老年肌少症营养肽
CN113288890A (zh) * 2021-06-21 2021-08-24 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Also Published As

Publication number Publication date
BR112019012476A2 (pt) 2020-04-14
ZA201903581B (en) 2020-12-23
PE20191206A1 (es) 2019-09-10
JOP20190147A1 (ar) 2019-06-18
CO2019006292A2 (es) 2019-06-28
US20180169047A1 (en) 2018-06-21
ECSP19043725A (es) 2019-07-31
MX2019007352A (es) 2019-09-05
CL2019001685A1 (es) 2019-08-30
EP3554493A1 (en) 2019-10-23
KR20190099243A (ko) 2019-08-26
PH12019501339A1 (en) 2019-09-30
WO2018118957A1 (en) 2018-06-28
IL267210A (en) 2019-08-29
TWI780096B (zh) 2022-10-11
US20180207119A1 (en) 2018-07-26
CU20190057A7 (es) 2020-02-04
MA50763A (fr) 2019-10-23
AU2017379825A1 (en) 2019-06-13
US20180169046A1 (en) 2018-06-21
CA3046558A1 (en) 2018-06-28
TW201827068A (zh) 2018-08-01
JP2020502183A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
TWI780096B (zh) 胺基酸組合物及肌肉疾病與病症之治療方法
US11571404B2 (en) Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
ES2660312T3 (es) Composición nutricional de bajo contenido calórico con alto contenido en proteínas para la estimulación de la síntesis de proteína muscular
US10973793B2 (en) Compositions and methods for the treatment of fat infiltration in muscle
WO2021178860A1 (en) Amino acid compositions and methods for muscle and myotube modulation
US20230044475A1 (en) Compositions and methods involving amino acids for the treatment of fat infiltrations in muscle
US20230105984A1 (en) Compositions and methods for the treatment of liver diseases and disorders
OA19826A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
OA20063A (en) Amino acid compositions for the treatment of liver disease.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination